Literature DB >> 19264906

Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.

Maria Letizia Taddei1, Matteo Parri, Adriano Angelucci, Barbara Onnis, Francesca Bianchini, Elisa Giannoni, Giovanni Raugei, Lido Calorini, Nadia Rucci, Anna Teti, Mauro Bologna, Paola Chiarugi.   

Abstract

Ligand-activated Eph tyrosine kinases regulate cellular repulsion, morphology, adhesion, and motility. EphA2 kinase is frequently up-regulated in several different types of cancers, including prostate, breast, colon, and lung carcinomas, as well as in melanoma. The existing data do not clarify whether EphA2 receptor phosphorylation or its simple overexpression, which likely leads to Eph kinase-independent responses, plays a role in the progression of malignant prostate cancer. In this study, we address the role of EphA2 tyrosine phosphorylation in prostate carcinoma cell adhesion, motility, invasion, and formation of metastases. Tumor cells expressing kinase-deficient EphA2 mutants, as well as an EphA2 variant lacking the cytoplasmic domain, are defective in ephrinA1-mediated cell rounding, retraction fiber formation, de-adhesion from the extracellular matrix, RhoA and Rac1 GTPase regulation, three-dimensional matrix invasion, and in vivo metastasis, suggesting a key role for EphA2 kinase activity. Nevertheless, EphA2 regulation of cell motility and invasion, as well as the formation of bone and visceral tumor colonies, reveals a component of both EphA2 kinase-dependent and -independent features. These results uncover a differential requirement for EphA2 kinase activity in the regulation of prostate carcinoma metastasis outcome, suggesting that although the kinase activity of EphA2 is required for the regulation of cell adhesion and cytoskeletal rearrangement, some distinct kinase-dependent and -independent pathways likely cooperate to drive cancer cell migration, invasion, and metastasis outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19264906      PMCID: PMC2671379          DOI: 10.2353/ajpath.2009.080473

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  57 in total

1.  Nuk controls pathfinding of commissural axons in the mammalian central nervous system.

Authors:  M Henkemeyer; D Orioli; J T Henderson; T M Saxton; J Roder; T Pawson; R Klein
Journal:  Cell       Date:  1996-07-12       Impact factor: 41.582

Review 2.  The Eph family: a multitude of receptors that mediate cell recognition signals.

Authors:  A H Zisch; E B Pasquale
Journal:  Cell Tissue Res       Date:  1997-11       Impact factor: 5.249

3.  Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands.

Authors:  S J Holland; N W Gale; G Mbamalu; G D Yancopoulos; M Henkemeyer; T Pawson
Journal:  Nature       Date:  1996-10-24       Impact factor: 49.962

4.  Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene.

Authors:  O Segatto; C R King; J H Pierce; P P Di Fiore; S A Aaronson
Journal:  Mol Cell Biol       Date:  1988-12       Impact factor: 4.272

5.  A new member of the Eph family of receptors that lacks protein tyrosine kinase activity.

Authors:  C B Gurniak; L J Berg
Journal:  Oncogene       Date:  1996-08-15       Impact factor: 9.867

6.  Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors.

Authors:  E Kiyokawa; S Takai; M Tanaka; T Iwase; M Suzuki; Y Y Xiang; Y Naito; K Yamada; H Sugimura; I Kino
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

7.  Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.

Authors:  Mark S Duxbury; Hiromichi Ito; Michael J Zinner; Stanley W Ashley; Edward E Whang
Journal:  Biochem Biophys Res Commun       Date:  2004-08-06       Impact factor: 3.575

8.  Redox regulation of ephrin/integrin cross-talk.

Authors:  Francesca Buricchi; Elisa Giannoni; Giovanna Grimaldi; Matteo Parri; Giovanni Raugei; Giampietro Ramponi; Paola Chiarugi
Journal:  Cell Adh Migr       Date:  2007-01-29       Impact factor: 3.405

Review 9.  Tyrosine kinase inhibitors in cancer therapy.

Authors:  Srinivasan Madhusudan; Trivadi S Ganesan
Journal:  Clin Biochem       Date:  2004-07       Impact factor: 3.281

10.  LMW-PTP is a positive regulator of tumor onset and growth.

Authors:  Paola Chiarugi; Maria Letizia Taddei; Nicola Schiavone; Laura Papucci; Elisa Giannoni; Tania Fiaschi; Sergio Capaccioli; Giovanni Raugei; Giampietro Ramponi
Journal:  Oncogene       Date:  2004-05-13       Impact factor: 9.867

View more
  57 in total

1.  Immunohistochemical demonstration of EphA2 processing by MT1-MMP in invasive cutaneous squamous cell carcinoma.

Authors:  Ryoko Tatsukawa; Kaori Koga; Mikiko Aoki; Naohiko Koshikawa; Shinichi Imafuku; Juichiro Nakayama; Kazuki Nabeshima
Journal:  Virchows Arch       Date:  2016-04-07       Impact factor: 4.064

2.  Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate screen identifies EphA2 as a target for LAR in cell migration.

Authors:  Hojin Lee; Anton M Bennett
Journal:  Mol Cell Biol       Date:  2013-01-28       Impact factor: 4.272

Review 3.  Eph- and ephrin-dependent mechanisms in tumor and stem cell dynamics.

Authors:  Erika Gucciardo; Nami Sugiyama; Kaisa Lehti
Journal:  Cell Mol Life Sci       Date:  2014-05-04       Impact factor: 9.261

4.  The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1).

Authors:  Bénédicte Foveau; Gaylor Boulay; Sébastien Pinte; Capucine Van Rechem; Brian R Rood; Dominique Leprince
Journal:  J Biol Chem       Date:  2011-12-19       Impact factor: 5.157

5.  Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck.

Authors:  Yong Liu; Xin Zhang; Yuanzheng Qiu; Donghai Huang; Shuai Zhang; Li Xie; Lin Qi; Changyun Yu; Xiaojuan Zhou; Guoqing Hu; Yongquan Tian
Journal:  J Cancer Res Clin Oncol       Date:  2010-07-08       Impact factor: 4.553

6.  Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer.

Authors:  Punit Saraon; Natasha Musrap; Daniela Cretu; George S Karagiannis; Ihor Batruch; Chris Smith; Andrei P Drabovich; Dominique Trudel; Theodorus van der Kwast; Colm Morrissey; Keith A Jarvi; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

7.  Increased expression of EphA1 protein in prostate cancers correlates with high Gleason score.

Authors:  Libo Peng; Haiyan Wang; Yingchun Dong; Jie Ma; Juanjuan Wen; Jinrong Wu; Xueqing Wang; Xiaojun Zhou; Jiandong Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

8.  EphA2-mediated mesenchymal-amoeboid transition induced by endothelial progenitor cells enhances metastatic spread due to cancer-associated fibroblasts.

Authors:  Elisa Giannoni; Maria Letizia Taddei; Matteo Parri; Francesca Bianchini; Michela Santosuosso; Renata Grifantini; Gabriella Fibbi; Benedetta Mazzanti; Lido Calorini; Paola Chiarugi
Journal:  J Mol Med (Berl)       Date:  2012-08-19       Impact factor: 4.599

Review 9.  Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.

Authors:  A M Traish; A Morgentaler
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

10.  Rac and Rho GTPases in cancer cell motility control.

Authors:  Matteo Parri; Paola Chiarugi
Journal:  Cell Commun Signal       Date:  2010-09-07       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.